Literature DB >> 12576099

VIP as a trophic factor in the CNS and cancer cells.

Terry W Moody1, Joanna M Hill, Robert T Jensen.   

Abstract

The effects of vasoactive intestinal peptide (VIP) on the proliferation of central nervous system (CNS) and cancer cells were investigated. VIP has important actions during CNS development. During neurogenesis, VIP stimulates the proliferation and differentiation of brain neurons. Addition of VIP to embryonic mouse spinal cord cultures increases neuronal survival and activity dependent neurotrophic factor (ADNF) secretion from astroglial cells. VIP is an integrative regulator of brain growth and development during neurogenesis and embryogenesis. Also, VIP causes increased proliferation of human breast and lung cancer cells in vitro. VIP binds with high affinity to cancer cells, elevates the cAMP and increases gene expression of c-fos, c-jun, c-myc and vascular endothelial cell growth factor. The effects of VIP on cancer cells are reversed by VIPhybrid, a synthetic VPAC(1) receptor antagonist. VIPhyb inhibits the basal growth of lung cancer cells in vitro and tumors in vivo and potentiates the ability of chemotherapeutic drugs to kill cancer cells. Due to the high density of VPAC(1) receptors in cancer cells, VIP has been radiolabeled with 123I, 18F and 99mTc to image tumors. It remains to be determined if radiolabeled VIP analogs will be useful agents for early detection of cancer in patients. Copyright 2002 Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576099     DOI: 10.1016/s0196-9781(02)00290-5

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  25 in total

1.  PYK-2 is tyrosine phosphorylated after activation of pituitary adenylate cyclase activating polypeptide receptors in lung cancer cells.

Authors:  Terry W Moody; Alessia Di Florio; Robert T Jensen
Journal:  J Mol Neurosci       Date:  2012-05-12       Impact factor: 3.444

2.  Genome-wide gene expression analysis of chemoresistant pulmonary carcinoid cells.

Authors:  Ulrike Olszewski; Robert Zeillinger; Klaus Geissler; Gerhard Hamilton
Journal:  Lung Cancer (Auckl)       Date:  2010-09-04

3.  Vasoactive Intestinal Peptide Promotes Corneal Allograft Survival.

Authors:  Vannarut Satitpitakul; Zhongmou Sun; Kunal Suri; Afsaneh Amouzegar; Kishore R Katikireddy; Ula V Jurkunas; Ahmad Kheirkhah; Reza Dana
Journal:  Am J Pathol       Date:  2018-08-07       Impact factor: 4.307

4.  Corneal endothelial autocrine VIP enhances its integrity in stored human donor corneoscleral explant.

Authors:  Shay-Whey M Koh; Dante Gloria; Joseph Molloy
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

5.  Vasoactive intestinal peptide signaling axis in human leukemia.

Authors:  Glenn Paul Dorsam; Keith Benton; Jarrett Failing; Sandeep Batra
Journal:  World J Biol Chem       Date:  2011-06-26

6.  Antiproliferative effects of PACAP and VIP in serum-starved glioma cells.

Authors:  Agata Grazia D'Amico; Soraya Scuderi; Salvatore Saccone; Alessandro Castorina; Filippo Drago; Velia D'Agata
Journal:  J Mol Neurosci       Date:  2013-07-31       Impact factor: 3.444

7.  Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons.

Authors:  Sara J Aton; Christopher S Colwell; Anthony J Harmar; James Waschek; Erik D Herzog
Journal:  Nat Neurosci       Date:  2005-03-06       Impact factor: 24.884

8.  Form deprivation modulates retinal neurogenesis in primate experimental myopia.

Authors:  Andrei V Tkatchenko; Pamela A Walsh; Tatiana V Tkatchenko; Stefano Gustincich; Elio Raviola
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

9.  Effects of PACAP and VIP on cAMP-generating system and proliferation of C6 glioma cells.

Authors:  Paulina Sokolowska; Jerzy Z Nowak
Journal:  J Mol Neurosci       Date:  2008-05-20       Impact factor: 3.444

10.  Form-deprivation myopia in chick induces limited changes in retinal gene expression.

Authors:  Alice M McGlinn; Donald A Baldwin; John W Tobias; Murat T Budak; Tejvir S Khurana; Richard A Stone
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-08       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.